Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarkar, S.
Right arrow Articles by Reznikoff, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarkar, S.
Right arrow Articles by Reznikoff, C. A.
[Cancer Research 60, 3862-3871, July 15, 2000]
© 2000 American Association for Cancer Research


Molecular Biology and Genetics

Different Combinations of Genetic/Epigenetic Alterations Inactivate the p53 and pRb Pathways in Invasive Human Bladder Cancers1

Somdatta Sarkar, Knut P. Jülicher, Melissa S. Burger, Véronique Della Valle, Christian-Jacques Larsen, Thomas R. Yeager, Timothy B. Grossman, Robert W. Nickells, Chris Protzel, David F. Jarrard and Catherine A. Reznikoff2

Departments of Human Oncology [S. S., K. P. J., M. S. B., D. F. J., C. A. R.], Surgery [D. F. J., T. B. G.], and Ophthalmology [R.W. N., C. P.], and the University of Wisconsin Medical School and Comprehensive Cancer Center [S. S., K. P. J., M. S. B., D. F. J., C. A. R., R. W. N., C. P.], Madison, Wisconsin 53792; Unité 434 INSERM Instituté de Génétique Moléculaire, 75010 Paris, France [V. D. V.]; Faculti des Sciences, 86100 Poitiers, France [C-J. L.]; and Cancer Research Unit, Children’s Medical Research Institute, Wentworthville, 2145 New South Wales Australia [T. R. Y.]

Inactivation of both the pRb (pRb-cyclin D1/cyclin-dependent kinase 4/6-p16) and p53 (p53-p21WAF1-p14ARF) pathways is thought to be essential for immortalization in vitro and malignant transformation in vivo. We identified different combinations of pRb and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the functional significance of the different combinations observed. Results showed four combinations of alterations including -pRb/-p53 (i.e., pRb inactivated in the pRb pathway and p53 inactivated in the p53 pathway; four TCCs), -p16/-p53 (four TCCs), -p16/-p21WAF1 (one TCC), and -p16/-p14ARF (two TCCs). These groups include two new combinations (i.e., -p16/-p53 and -p16/-p21WAF1) not reported previously for TCCs. An alteration in the key components of the p53 pathway was not detected in one invasive TCC that had inactivated p16. Note that all four TCCs with inactivated pRb had mutant p53; thus, the combinations of -pRb/-p21WAF1 and -pRb/-p14ARF were not observed. Only two of eight TCCs with altered p16 had concomitant p14ARF loss, demonstrating that simultaneous inactivation of these two 9p21INK4a tumor suppressor genes is not obligatory. To determine the biological phenotypes of TCCs with different combinations of pRb and p53 pathway alterations, their downstream responses to gamma radiation were studied in vitro. As expected, none of eight TCCs with mutant p53 responded to gamma radiation by elevation of p53, p21WAF1, or mdm2 or by cell cycle arrest. Only two of four TCCs with wild-type p53 and wild-type pRb (the combination of -p16/-p14ARF) showed normal downstream responses to gamma radiation and underwent cell cycle arrest. Two TCCs with wild-type pRb and wild-type p53 (the combination of -p16/-p21WAF1 and one TCC with -p16) failed to show cell cycle arrest in response to radiation. This was attributed to the absence of p21WAF1 in one TCC. In summary, these data support a model of invasive bladder cancer pathogenesis in which both the pRb and p53 pathways are usually inactivated and the biology of the tumor is impacted by the mechanism of their inactivations.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
L. S. Pymar, F. M. Platt, J. M. Askham, E. E. Morrison, and M. A. Knowles
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
Hum. Mol. Genet., July 1, 2008; 17(13): 2006 - 2017.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. J. MacLaine, M. D. Wood, J. C. Holder, R. W. Rees, and J. Southgate
Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway
Mol. Cancer Res., January 1, 2008; 6(1): 53 - 63.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Sanchez-Carbayo, N. D. Socci, T. Kirchoff, N. Erill, K. Offit, B. H. Bochner, and C. Cordon-Cardo
A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer
Clin. Cancer Res., June 1, 2007; 13(11): 3215 - 3220.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R.A. Crallan, N.T. Georgopoulos, and J. Southgate
Experimental models of human bladder carcinogenesis
Carcinogenesis, March 1, 2006; 27(3): 374 - 381.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Garcia-Espana, E. Salazar, T.-T. Sun, X.-R. Wu, and A. Pellicer
Differential Expression of Cell Cycle Regulators in Phenotypic Variants of Transgenically Induced Bladder Tumors: Implications for Tumor Behavior
Cancer Res., February 15, 2005; 65(4): 1150 - 1157.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H.-S. Hsu, Y.-C. Wang, R.-C. Tseng, J.-W. Chang, J.-T. Chen, C.-M. Shih, C.-Y. Chen, and Y.-C. Wang
CpG Island Methylation Is Responsible for p14ARF Inactivation and Inversely Correlates with p53 Overexpression in Resected Non-Small Cell Lung Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4734 - 4741.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. De Flora, R. M. Balansky, F. D'Agostini, A. Izzotti, A. Camoirano, C. Bennicelli, Z. Zhang, Y. Wang, R. A. Lubet, and M. You
Molecular Alterations and Lung Tumors in p53 Mutant Mice Exposed to Cigarette Smoke
Cancer Res., February 15, 2003; 63(4): 793 - 800.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. R. Schwarze, S. E. DePrimo, L. M. Grabert, V. X. Fu, J. D. Brooks, and D. F. Jarrard
Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells
J. Biol. Chem., April 19, 2002; 277(17): 14877 - 14883.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. F. Garcia, R. Villuendas, M. Sanchez-Beato, A. Sanchez-Aguilera, L. Sanchez, I. Prieto, and M. A. Piris
Nucleolar p14ARF Overexpression in Reed-Sternberg Cells in Hodgkin's Lymphoma : Absence of p14ARF/Hdm2 Complexes Is Associated with Expression of Alternatively Spliced Hdm2 Transcripts
Am. J. Pathol., February 1, 2002; 160(2): 569 - 578.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. D.C. Markl, J. Cheng, G. Liang, D. Shibata, P. W. Laird, and P. A. Jones
Global and Gene-specific Epigenetic Patterns in Human Bladder Cancer Genomes Are Relatively Stable in Vivo and in Vitro over Time
Cancer Res., August 1, 2001; 61(15): 5875 - 5884.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.